Clinical Trials Logo

Clinical Trial Summary

The objective of this study is to investigate whether the IOP (intraocular pressure) -lowering effect of DE-111A (preservative-free fixed dose combination of 0.0015% tafluprost and 0.5% timolol eye drops, administered one drop a time, once daily for 3 months) is superior to the monotherapy of tafluprost 0.0015% eye drops administered one drop a time, once daily for 3 months) in subjects with open-angle glaucoma or ocular hypertension in China as well as comparison of safety.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT03822559
Study type Interventional
Source Santen Pharmaceutical Co., Ltd.
Contact Santen Pharmaceutical Co., Ltd.
Phone +81-6-4802-9338
Status Recruiting
Phase Phase 3
Start date January 20, 2019
Completion date June 30, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT03216902 - A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study Phase 2
Recruiting NCT03858894 - Double-Masked Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6 Phase 2